Venetoclax, Bendamustine, and Rituximab in Refractory NHL Venetoclax, Bendamustine, and Rituximab in Refractory NHL

A study has established the safety profile of the anti-apoptotic B-cell leukemia/lymphoma-2 protein venetoclax in combination with bendamustine and rituximab.Annals of Oncology

Source: Medscape Today Headlines - October 26, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news